You scroll past an advert promising to decode your gut bacteria with a simple test kit, then deliver personalised diet advice to transform your digestion. It sounds appealing, especially if you live with inflammatory bowel disease (IBD) and want answers beyond your latest calprotectin result. But what do these tests actually measure, and can they guide clinical decisions for Crohn’s disease or ulcerative colitis?
What Are At-Home Gut Microbiome Tests?
At-home gut microbiome tests analyse the composition of bacteria and other microorganisms in your stool. You collect a sample at home, post it to a laboratory, and receive a report detailing which species are present and in what relative abundance. Some companies compare your results to a reference population and suggest dietary changes or supplements. Most use 16S ribosomal RNA gene sequencing or shotgun metagenomic sequencing to identify microbial DNA in your sample.
How They Work
The test measures genetic material from bacteria in your stool, not live organisms. The laboratory amplifies bacterial DNA and assigns sequences to known taxonomic groups, generating a list of microbes and their relative proportions. Results typically show a percentage breakdown of phyla, genera, or species, alongside diversity scores. Some tests report metabolic potential (genes encoding enzymes to produce certain metabolites), though this does not confirm those metabolites are actually being made.
Why Microbiome Composition Matters in IBD
The gut microbiome regulates intestinal immunity and maintains the gut barrier. In IBD, microbial diversity is often reduced, with relative loss of anti-inflammatory bacteria and increases in species that may promote inflammation. Changes in bacterial composition affect availability of short-chain fatty acids, particularly butyrate, which nourishes colonic cells and modulates immune responses. Specific bacteria also interact with bile acids and affect T-cell differentiation, influencing whether the immune system tilts toward inflammation or tolerance.
However, the microbiome fluctuates with diet, medication, stress, infection, and disease activity. A single snapshot does not capture this variability, and the clinical significance of any particular bacterial profile remains uncertain.
What These Tests Can and Cannot Tell You
What They Measure
At-home tests identify which bacterial taxa are present in your stool and their relative abundance. They show whether your diversity is higher or lower than a reference group and whether certain groups, such as Firmicutes or Bacteroidetes, dominate. Some flag the presence or absence of specific genera associated with gut health, such as Faecalibacterium or Akkermansia.
What They Do Not Measure
These tests do not diagnose IBD, predict flares, or measure disease activity. They cannot replace faecal calprotectin, C-reactive protein, endoscopy, or histology. They do not confirm whether inflammation is present or whether a particular bacterium is causing symptoms. Correlation between microbial composition and clinical outcomes in IBD is still being studied, and no commercially available test has been validated to guide treatment decisions.
The Problem with Personalised Recommendations
Many companies provide dietary advice based on your microbial profile. These recommendations are often generic and not tailored to IBD. Some suggest increasing fibre or resistant starch to feed beneficial bacteria, but for someone with active inflammation or strictures, such advice may worsen symptoms or be unsafe. Evidence linking specific dietary changes to targeted microbial shifts and improved clinical outcomes in IBD is limited.
Clinical Context and Evidence Gaps
Research shows people with IBD tend to have altered microbial communities compared to healthy controls, but there is no single IBD microbiome signature. Variability between individuals is high, and the same profile can be found in people with and without disease. Faecal microbiota transplantation has shown promise in ulcerative colitis in controlled trials, suggesting microbial manipulation can influence disease, but mechanisms are complex and not well understood. At-home tests do not assess microbial function, gut barrier integrity, or host immune responses, all critical in IBD.
When Might a Test Be Useful?
For most people with IBD, at-home microbiome tests do not change clinical management. They may offer value in specific research or exploratory contexts. If you are curious about your microbial composition and understand the limitations, a test can provide a snapshot at one point in time. It may be useful when tracking changes during a specific dietary intervention under professional guidance, though you should not use results to alter medication or make major dietary changes without consulting your gastroenterologist or dietitian.
What to Consider Before Ordering
Cost and Value
These tests typically cost between £100 and £300. Consider whether that investment will yield actionable information or simply confirm that your gut bacteria are affected by your condition.
Accuracy and Interpretation
Different companies use different methods, reference databases, and algorithms. Results may vary between tests, even from the same sample. Interpretation is not standardised, and reports are not reviewed by a clinician who knows your medical history.
Risk of Misinterpretation
Without proper context, results can be misleading. Low abundance of a particular species does not necessarily mean you need to supplement with a probiotic containing that strain. Microbial ecology is complex, and single-species interventions may not translate into meaningful clinical benefit.
Practical Takeaways
- At-home microbiome tests provide a snapshot of bacterial composition but do not diagnose IBD, measure inflammation, or predict flares.
- Dietary recommendations based on these tests are not tailored to IBD and may conflict with clinical guidance for active disease or strictures.
- Do not use test results to adjust medication or make major dietary changes without input from your gastroenterology team.
- If you are interested in testing, discuss it with your dietitian or consultant to ensure any findings are interpreted in the context of your condition.
- Focus on consistent, evidence-based dietary and lifestyle strategies rather than chasing fluctuating microbial metrics.
Conclusion
At-home gut microbiome tests offer an intriguing glimpse into the microbial world, but they are not yet a clinical tool for managing IBD. They cannot replace established markers of disease activity or guide treatment decisions. For most people, the money and effort may be better spent working with a specialist dietitian or focusing on well-established dietary strategies that support gut health. If you do choose to test, interpret the results with caution and always seek professional input before making changes to your care.
References
- Halfvarson J, Brislawn CJ, Lamendella R, et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat Microbiol. 2017;2:17004. doi:10.1038/nmicrobiol.2017.4
- Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655-662. doi:10.1038/s41586-019-1237-9
- Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat Microbiol. 2019;4(2):293-305. doi:10.1038/s41564-018-0306-4
- Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA. 2019;321(2):156-164. doi:10.1001/jama.2018.20046
- Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-1228. doi:10.1016/S0140-6736(17)30182-4
- Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15(3):382-392. doi:10.1016/j.chom.2014.02.005
- Sartor RB, Wu GD. Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152(2):327-339.e4. doi:10.1053/j.gastro.2016.10.012
- Ananthakrishnan AN, Luo C, Yajnik V, et al. Gut microbiome function predicts response to anti-integrin biologic therapy in inflammatory bowel diseases. Cell Host Microbe. 2017;21(5):603-610.e3. doi:10.1016/j.chom.2017.04.010
This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.